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The	   aim	  of	   this	   study	  was	   to	   determine	   the	   safety	   and	   clinical	   effectiveness	   of	   10Fr	  
plastic	   biliary	   stents	   compared	   to	   uncovered	   self-­‐expanding	  metal	   stents	   (SEMS)	   for	  
palliative	  treatment	  of	  patients	  with	  inoperable	  malignant	  distal	  biliary	  obstruction	  in	  a	  
public	  hospital	  in	  South	  Africa.	  
Methods	  
From	   January	  2009	   to	  December	  2013,	   40	  patients	  who	  were	   admitted	   to	   a	   tertiary	  
academic	   centre	   because	   of	   distal	   malignant	   biliary	   obstruction	   were	   enrolled	   in	   a	  
prospective	   randomised	  study.	  Patients	  were	   randomly	  assigned	   to	   receive	  either	  an	  
uncovered	   SEMS	   or	   a	   plastic	   stent	   deployed	   through	   the	   biliary	   stricture	   during	  
endoscopic	  retrograde	  cholangiopancreatography.	  
Results	  
Patient	  survival	  time	  in	  the	  two	  groups	  did	  not	  differ	  significantly	  (median:	  SEMS	  -­‐	  114	  
days;	  plastic	  -­‐	  107	  days)	  (p=0.181).	  Stent	  failure	  was	  more	  common	  in	  the	  plastic	  stent	  
group	   (7/19	   vs.	   1/20)	   (p=0.043).	   The	   results	   became	   significant	   after	   6	   months	   of	  
follow	  up.	  There	  was	  no	  significant	  difference	  between	  the	  two	  groups	  in	  the	  incidence	  
of	  serious	  adverse	  events.	  
Conclusions	  
SEMS	  had	  a	  longer	  duration	  of	  patency	  than	  plastic	  stents,	  which	  favours	  their	  use	  in	  
the	   palliative	   treatment	   of	   patients	   with	   biliary	   obstruction	   due	   to	   distal	   malignant	  
biliary	  obstruction.	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  retrograde	  cholangio-­‐pancreatography	  
SEMS	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Chapter	  1:	  Introduction	  
1.1 Context	  and	  Literature	  
1) Introduction
Tumours	  causing	  malignant	  distal	  biliary	  obstruction	  may	  originate	  in	  the	  head	  of	  the	  
pancreas,	   ampulla	   or	   distal	   common	   bile	   duct.	   Head	   of	   pancreas	   ductal	  
adenocarcinoma	  accounts	   for	  about	   two-­‐thirds	  of	  periampullary	   cancers	   followed	  by	  
ampullary	  cancer	  (about	  20%)	  and	  distal	  cholangiocarcinoma	  (about	  15%)1.	  
Despite	   improvements	   in	   surgical	   technique,	   critical	   care,	   radiotherapy	   and	  
chemotherapy	  the	  survival	  of	  patients	  with	  periampullary	  cancer	  remains	  poor	  and	  has	  
not	   improved	   significantly	   over	   the	   last	   30	   years.	   The	   overall	   5-­‐year	   survival	   of	  
pancreatic	   ductal	   adenocarcinoma	   is	   still	   only	   about	   5%1.	   Although	   there	   have	   been	  
recent	  advances	  in	  the	  molecular	  subtyping	  of	  pancreatic	  cancer,	  which	  have	  helped	  in	  
the	   understanding	   of	   the	   complex	   biology	   of	   the	   tumour,	   these	   developments	   have	  
not	  yet	  translated	  into	  new	  treatments2-­‐5.	  
Tumours	   causing	   distal	   malignant	   biliary	   obstruction	   are	   often	   asymptomatic	   in	   the	  
early	  stages	  and	  80%	  of	  patients	  are	  not	  candidates	  for	  surgical	  resection	  and	  require	  
palliative	   treatment.	   The	   most	   common	   symptoms	   that	   require	   palliation	   are	  
obstructive	  jaundice,	  gastric	  outlet	  obstruction	  and	  pain.	  Seventy	  to	  ninety	  percent	  of	  
patients	  with	  periampullary	  cancers	  have	  obstructive	  jaundice	  at	  presentation.	  Before	  
the	  1980s	  the	  only	  means	  for	  effective	  palliation	  of	  obstructive	  jaundice	  was	  a	  surgical	  
9	  
bypass.	  In	  some	  series	  as	  many	  as	  57%	  of	  patients	  with	  unresectable	  pancreatic	  cancer	  
underwent	  a	  surgical	  bypass.	  Operative	  palliation	  has	  since	  been	  replaced	  with	  biliary	  
stenting,	   either	   via	   percutaneous	   access	   or	   via	   endoscopic	   retrograde	   cholangio-­‐
pancreatography	   (ERCP).	   There	   are	   advantages	   and	   disadvantages	   to	   each	   of	   these	  
three	  techniques	  and	  these	  need	  to	  be	  taken	  into	  account	  when	  deciding	  on	  the	  best	  
option	  for	  each	  patient6-­‐8.	  	  
2) Historical	  perspective
The	   first	   endoscopic	   biliary	   stent	   insertion,	   using	   a	  modified	   7Fr	   angiographic	   pigtail	  
catheter,	   was	   performed	   in	   19799.	   Initial	   duodenoscopes	   had	   relatively	   small	  
instrumentation	  channels	  which	  limited	  the	  passage	  of	  larger	  stents.	  There	  was	  a	  high	  
incidence	  of	  cholangitis	  due	  to	  stent	  occlusion	  that	  was	  attributed	  to	  the	  small	  calibre	  
of	  the	  prostheses	  that	  were	  being	  used9,10.	  
Huibregtse	   and	   colleagues	   were	   the	   first	   to	   insert	   a	   larger	   stent	   in	   Amsterdam	   in	  
198111.	   It	   was	   placed	   with	   a	   forward	   viewing	   gastroscope	   and	   was	   a	   straight	   10FR	  
polyethylene	  stent	  with	  flaps	  on	  either	  end.	  This	  type	  of	  stent	   is	  often	  referred	  to	  as	  
the	  Cotton-­‐Huibregtse	  or	  Amsterdam	  type	  stent.	  The	  first	  duodenoscopes	  with	  larger	  
(3.7mm)	  instrumentation	  channels,	  capable	  of	  passing	  10Fr	  stents	  were	  developed	  in	  
1981.	   This	   simplified	   the	   process	   of	   placing	   10Fr	   stents	   and	   in	   1982	   the	  Amsterdam	  
group	   published	   a	   series	   of	   45	   patients	  with	   obstructive	   jaundice	   that	  were	   treated	  
with	   10Fr	   polyethylene	   stents.	   Jaundice	   improved	   in	   43	   patients.	   Eleven	   patients	  
developed	  cholangitis.	  These	  results	  were	  significantly	  better	  than	  with	  the	  7Fr	  stents.	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Endoscopic	   stenting	   became	   a	   well	   established	   palliative	   treatment	   modality	   in	   the	  
mid	   1980s,	   as	   the	   technical	   success	   rates	   of	   endoscopic	   stenting	   for	   distal	   biliary	  
strictures	  improved11-­‐13.	  
The	   first	   report	   of	   a	   expandable	   metal	   mesh	   tube,	   the	   prelude	   to	   modern	   self	  
expanding	   metal	   stents	   (SEMS),	   dates	   back	   to	   the	   early	   1970s	   with	   the	   so	   called	  
Didcott	   dilator	   which	   was	   used	   to	   treat	   oesphageal	   strictures.	   Colin	   Didcott	   was	   a	  
South	  African	  trained	  surgeon	  and	  developed	  the	  stents	  while	  working	  in	  South	  Africa,	  
Rhodesia	   and	   the	   United	   Kingdom14-­‐16.	   The	   first	   reports	   of	   SEMS	   being	   used	   for	  
treatment	   of	   biliary	   strictures	   were	   published	   in	   198916,17.	   The	   initial	   SEMS	   were	  
uncovered	   and	   constructed	   from	   stainless	   steel	   with	   a	   diameter	   of	   8-­‐10mm	   (when	  
deployed)	  17,18.	  
Nitinol	   is	  a	  nickel-­‐titanium	  alloy	  that	  has	  properties	  of	  shape	  memory,	  superelasticity	  
and	   force	  hysteresis.	   The	  properties	  of	  Nitinol	  were	  discovered	   in	  1959	  at	   the	  Naval	  
Ordnance	   Laboratory	   in	  Maryland,	  USA.	   These	   properties	   are	   useful	  when	   designing	  
and	   constructing	   SEMS	   and	   the	   majority	   of	   commercially	   available	   SEMS	   are	  
constructed	   from	  nitinol19-­‐21.	  Covered	  and	  partially	   covered	  SEMS	  were	  developed	   in	  
the	   1990s	   in	   an	   attempt	   to	   prolong	   stent	   patency	   by	   reducing	   tumour	   ingrowth.	  
Covered	  stents	  do	  not	  embed	  in	  the	  bile	  duct	  to	  the	  same	  extent	  as	  uncovered	  stents	  
making	  them	  easier	  to	  remove	  but	  also	  more	  likely	  to	  migrate	  than	  uncovered	  SEMS22.	  
Apart	  from	  feasibility	  and	  safety	  studies,	  trials	  of	  biliary	  stents	  can	  be	  divided	  into	  four	  
main	  groups,	  which	  are	  grouped	  as	  follows:	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a) Trials	  comparing	  the	  efficacy	  of	  different	  types	  of	  plastic	  stents
b) Trials	  comparing	  biliary	  stents	  to	  surgical	  bypass
c) Trials	  comparing	  plastic	  stents	  to	  SEMS
d) Trials	  comparing	  different	  types	  of	  SEMS
3) Plastic	  stents
Trials	   comparing	   different	   stent	   materials	   and	   calibres	   are	   summarized	   in	   Table	   1.	  
Different	   materials,	   size	   and	   shapes	   have	   been	   used	   in	   an	   attempt	   to	   develop	   the	  
optimal	  plastic	   stent.	  The	   ideal	   stent	   should	  be	   technically	  easy	   to	   insert,	   should	  not	  
occlude	  and	  should	  not	  injure	  the	  bile	  duct	  or	  duodenum23.	  Stent	  calibres	  from	  7Fr	  to	  
12Fr	  have	  been	  tested.	  As	  the	  stent	  calibre	  increases	  above	  10Fr	  the	  technical	  difficulty	  
of	  stent	  insertion	  increases.	  Increasing	  stent	  calibre	  above	  10Fr	  does	  not	  improve	  stent	  
patency.	  Hence,	  a	  diameter	  of	  10Fr	  is	  thought	  to	  be	  the	  best	  combination	  of	  patency	  
and	  ease	  of	  stent	  insertion13,24-­‐26.	  
Polyethylene,	   polyurethane	   and	  polytetrafluoroethylene	   (Teflon)	   have	  been	  used	   for	  
plastic	  stents.	  The	  characteristics	  of	  the	  different	  materials	  are	  tabulated	  in	  Table	  227.	  
Teflon	  has	  a	  lower	  coefficient	  of	  friction	  than	  polyethylene	  and	  polyurethane.	  In	  vitro	  
studies	   showed	   a	   direct	   correlation	   between	   the	   coefficient	   of	   friction	   and	   stent	  
clogging.	  Teflon	  has	  the	  lowest	  coefficient	  of	  all	  polymers	  but	  this	  benefit	  has	  not	  been	  
demonstrated	   in	   clinical	   practice.	   A	   meta-­‐analysis	   suggested	   better	   patency	   of	  
polyethylene	   stents	   in	  distal	  malignant	  biliary	  obstruction	   compared	   to	  Teflon	   stents	  
although	  the	  differences	  were	  not	  statistically	  significant27-­‐30.	  Polyurethane	  stents	  have	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not	  been	  shown	  to	  have	  better	  patency	  than	  Teflon	  or	  polyethylene	  stents	  and	  tend	  to	  
become	  brittle	  over	  time	  and	  frequently	  fragment	  during	  attempted	  removal31,32.	  
Various	  stent	  designs	  have	  been	  attempted	  to	  decrease	  stent	  blockage.	  Flanged	  stents	  
which	  have	  a	  single	  flap	  and	  a	  side	  hole	  proximally	  and	  distally	  (Cotton-­‐Huibregste	  or	  
Amsterdam	  type	  stent)	  are	  most	  commonly	  used.	  These	  stents	  may	  be	  straight,	  angled	  
or	   curved.	   The	   addition	   of	   side	   holes	   along	   the	   entire	   length	   of	   the	   stent	   has	   been	  
shown	   to	   increase	   the	   incidence	   of	   stent	   occlusion	   which	   is	   thought	   to	   be	   due	   to	  
slower	  bile	   transit	   though	  the	  stent23.	  The	  Tannenbaum	  stent	  with	  two	  proximal	  and	  
two	  distal	   flaps	   (with	  or	  without	  side	  holes)	  was	  developed	   in	  199433.	   Initial	   superior	  
results,	   comparing	   the	   stent	   to	   conventional	   plastic	   stents,	   in	   prospective	   non-­‐
randomised	   trials	   were	   encouraging	   but	   could	   not	   be	   confirmed	   in	   subsequent	  
randomised	   control	   trials.	   Three	   studies	   showed	   a	   higher	   risk	   of	   therapeutic	   failure	  
with	  10Fr	  Tannenbaum	  Teflon	  stents	  compared	  to	  conventional	  polyethylene	  stents34-­‐
36.	  
The	  addition	  of	  an	  anti-­‐reflux	  valve	  at	  the	  end	  of	  the	  stent	  preventing	  reflux	  of	  material	  
from	  the	  duodenum	  into	  the	  stent	  has	  not	  been	  shown	  to	  improve	  patency	  rates.	  The	  
use	  of	  a	  star	  shaped	  stent	  with	  a	   limited	  central	   lumen	  has	  also	  been	  attempted	  but	  
was	   not	   shown	   to	   be	   beneficial37,38.	   Various	   other	  modifications	   have	   been	   tried	   in	  
attempts	   to	   decrease	   biofilm	   creation	   to	   prolong	   stent	   patency.	   These	   include	  
specialized	   coatings	   and	   double	   layer	   design.	   To	   date	   no	   studies	   on	   these	  modified	  
stents	  have	  shown	  increases	  in	  stent	  patency23.	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Table	  1.	  Trials	  comparing	  various	  types	  of	  plastic	  stents13,24,26,28,31,32,36,39	  
Study	   Study	  type	   Comparison	   Patients	   Result	  
Speer	  (1988)	   Retrospective	  
analysis	  
8Fr	  polyethylene	  pigtail	  
stents	  vs.	  straight	  10Fr	  
polyethylene	  stents	  
65	   Significantly	  
lower	  incidence	  
of	  cholangitis	  
with	  10Fr	  vs.	  8Fr	  






10Fr	  vs.	  11Fr	  
polyethylene	  stents	  
(Amsterdam	  type)	  







10Fr	  vs.	  11.5Fr	  
polyethylene	  stents	  
(Amsterdam	  type)	  







10Fr	  polyethylene	  vs.	  
10Fr	  Teflon	  stents	  
(Amsterdam	  type)	  
84	   No	  significant	  
difference	  in	  
stent	  patency	  













10Fr	  Teflon	  Tannenbaum	  
vs.	  10Fr	  polyethylene	  
stents	  (Amsterdam	  type)	  







10Fr	  hydromer	  coated	  
polyurethane	  stents	  vs.	  
10Fr	  polyethylene	  stents	  
(Amsterdam	  type)	  







10Fr	  polyurethane	  vs.	  
10Fr	  polyethylene	  stents	  
(Amsterdam	  type)	  




Table	  2.	  Characteristics	  of	  commonly	  used	  materials	  for	  plastic	  stents27	  
Polyethylene	   Polyurethane	   Polytetrafluroethylene	  
Coefficient	  of	  
friction	  







Smooth	   Irregular	  with	  pits	  and	  
ridges	  
Other	   Soft	   Becomes	  brittle	  
with	  time	  
Stiff,	  higher	  incidence	  
of	  perforation	  in	  some	  
studies	  
4) Surgery	  compared	  to	  stenting
Various	   surgical	   procedures	   can	   be	   used	   for	   biliary	   drainage.	   Historically	   external	  
drainage	  with	  a	  T-­‐tube	  was	  used.	  This	  was	  associated	  with	  fluid	  and	  electrolyte	  losses	  
and	   the	   associated	   complications	   thereof.	   Internal	   drainage	   is	   thus	   preferred	   with	  
cholecystojejunostomy,	   hepaticojejunostomy,	   choledochojejunostomy	   or	  
choledochoduodenostomy40.	   Cholecystojejunostomy	   is	   a	   relatively	   simple	   procedure	  
but	   has	   been	   shown	   to	   have	   a	   higher	   rate	   of	   recurrent	   jaundice	   and	   cholangitis	  
compared	  to	  a	  hepaticojejunostomy.	  Choledochoduodenotomy	  results	  in	  a	  higher	  rate	  
of	  recurrent	   jaundice	  compared	  to	  a	  hepaticojejunostomy,	  due	  to	  tumour	   infiltration	  
into	  the	  duodenum	  and	  distal	  common	  bile	  duct40-­‐42.	  
Five	  randomised	  controlled	  trials	  have	  compared	  percutaneous	  or	  endoscopic	  stenting	  























































































































































































































































































































































































































































The	   Bornman	   study	   compared	   percutaneous	   transhepatic	   biliary	   stenting	   to	   surgical	  
drainage	   whereas	   the	   other	   four	   studies	   compared	   endoscopic	   stent	   insertion	   to	  
surgical	  bypass.	  Deficiencies	  in	  the	  studies	  included	  small	  numbers	  of	  patients,	  poorly	  
defined	  outcomes	  and	   inadequate	  blinding43.	  Furthermore,	   there	  was	  no	  consistency	  
in	  the	  definition	  of	  serious	  complications.	  The	  only	  study	  to	  evaluate	  quality	  of	  life	  was	  
by	   Smith	   et.	   al.	   which	   also	   included	   the	   largest	   number	   of	   patients48.	   It	   has	   been	  
suggested	  that	  the	  stent	  arm	  results	  in	  these	  studies	  would	  have	  been	  better	  if	  SEMS	  
had	  been	  used49.	  However	   the	  Nieveen	   study,	   the	  only	   study	   to	  use	   SEMS,	   included	  
only	   a	   small	   number	   of	   patients	   and	   the	   incidence	   of	   recurrent	   jaundice	   was	   not	  
mentioned.	   Forty	   three	   percent	   of	   the	   stented	   patients	   in	   this	   study	   developed	   a	  
complication	   during	   follow	   up	   compared	   to	   32%	   of	   the	   patients	   who	   underwent	   a	  
surgical	  bypass	  procedure.	  
Despite	  the	   limitations	  mentioned	  above	  some	  conclusions	  can	  be	  drawn	  from	  these	  
studies.	  Surgical	  treatment	  is	  associated	  with	  a	  higher	  early	  morbidity,	  a	  higher	  30-­‐day	  
mortality,	   and	   a	   longer	   initial	   hospital	   stay	   compared	   to	   endoscopic	   stent	   insertion.	  
Although	  there	   is	  an	   initially	   lower	  morbidity	  and	  mortality	   in	  endoscopically	   treated	  
patients	  they	  have	  a	  higher	  incidence	  of	  recurrent	  jaundice,	  are	  more	  likely	  to	  require	  
re-­‐interventions	   and	  have	  more	   readmissions.	   There	  was	   no	   significant	   difference	   in	  
the	  overall	  survival	  between	  the	  two	  groups.	  
5. Plastic	  vs.	  Self-­‐Expanding	  Metal	  Stent
Seven	  prospective	  trials	  have	  been	  published	  comparing	  plastic	  stents	  and	  SEMS	  (Table	  
4)50-­‐56.	  Technical	  success	  and	  complication	  rates	  related	  to	  stent	  insertion	  were	  similar.
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Plastic	   stents	  had	  a	  higher	  occlusion	   rate	  and	  shorter	  patency	  duration	  compared	   to	  
SEMS.	  There	  was	  no	   significant	  difference	   in	   survival	   in	  any	  of	   the	   trials.	  As	  patients	  
with	  plastic	  stents	  are	  more	  likely	  to	  develop	  recurrent	  jaundice	  they	  were	  more	  likely	  
to	   require	   additional	   interventions,	   accounting	   for	   the	   longer	   hospital	   stay	   and	   the	  
higher	   number	   of	   ERCPs	   in	   the	   plastic	   stent	   groups.	   Plastic	   stents	   have	   some	  
advantages	   over	   SEMS.	   Should	   the	   need	   arise	   they	   can	   be	   easily	   removed,	  which	   is	  
useful	   in	   situations	   where	   the	   diagnosis	   of	  malignancy	   has	   not	   been	   established.	   In	  
addition	  plastic	  stents	  are	  cheaper	  than	  SEMS.	  A	  cost	  analysis	  was	  performed	  in	  most	  
of	  the	  above	  trials.	  The	  methodology	  of	  calculating	  the	  costs	  is	  not	  described	  in	  detail	  
in	  any	  of	  the	  trials	  and	  in	  some	  of	  the	  trials	  there	  is	  only	  an	  estimation	  of	  cost.	  
The	  additional	  cost	  of	  SEMS	  is	  offset	  by	  the	  expense	  of	  additional	  hospital	  admissions	  
and	  procedures	  related	  to	  stent	  dysfunction,	  which	  is	  more	  likely	  with	  a	  plastic	  stent57.	  
The	   cost	   benefit	   of	   plastic	   stents	   decreases	  with	   increased	   survival,	   as	   patients	  who	  
survive	   longer	  are	  more	   likely	   to	  develop	  stent	  dysfunction.	  Yeoh	  et.	  al.	  performed	  a	  
comparative	  cost	  analysis	  of	  metal	  and	  plastic	  biliary	  stents	  for	  malignant	  obstructive	  
jaundice57.	  The	  cost	  of	  a	  particular	  stent	  strategy	  depends	  on	  the	  cost	  of	  the	  respective	  
stents	   relative	  to	  the	  procedural	  costs	  of	  an	  ERCP	  and	  patient	  survival.	   In	   the	  United	  
States	  healthcare	  environment	  a	  plastic	  stent	  strategy	  was	  less	  costly	  for	  patients	  who	  
survived	   less	   than	   4	   months.	   The	   presence	   of	   metastatic	   disease	   and	   poor	  
performance	  status	  are	  the	  most	  accurate	  predictors	  of	  poor	  survival.	   It	   is	  suggested	  
that	   these	   two	   indicators	   should	   be	   used	   to	   identify	   patients	   with	   limited	   life	  
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6. Different	  Types	  of	  Metal	  Stents
There	  are	  three	  main	  types	  of	  SEMS,	  namely	  uncovered,	  partially	  covered	  and	  fully	  
covered.	  Covered	  stents	  were	  developed	  to	  prevent	  tumour	  ingrowth,	  which	  is	  a	  
common	  cause	  for	  obstruction	  of	  uncovered	  stents.	  The	  first	  covered	  stents	  were	  
developed	  in	  Japan	  in	  1994.	  Various	  materials	  have	  been	  evaluated	  for	  the	  covering	  
membrane	  including	  polyurethane,	  Gore-­‐Tex	  and	  silicone59.	  
The	  advantages	  and	  disadvantages	  of	  the	  various	  stents	  are	  tabulated	  in	  Table	  5.	  
Covered	  and	  partially	  covered	  SEMS	  may	  occlude	  the	  pancreatic	  and	  cystic	  ducts	  
causing	  pancreatitis	  or	  cholecystitis.	  In	  addition	  covered	  stents	  are	  more	  prone	  to	  
migration.	  
Table	  5.	  Characteristics	  with	  potential	  advantages/disadvantages	  of	  uncovered	  and	  
covered	  SEMS60	  
Type	  of	  SEMS	   Advantages	   Disadvantages	  
Uncovered	   Low	  probability	  of	  migration	  
Less	  shortening	  than	  covered	  
stents	  making	  deployment	  
easier	  
Obstruction	  by	  tumour	  
ingrowth	  
Removal	  difficult	  
Partially	  Covered	   No	  tumour	  ingrowth	  




more	  likely	  than	  with	  a	  
fully	  covered	  stent	  
Fully	  Covered	   No	  tumour	  ingrowth	  
Removal	  -­‐	  high	  possibility	  
Migration	  
Pancreatitis/cholecystitis	  
There	  have	  been	  a	  number	  of	  prospective	  randomised	  trials	  and	  three	  meta-­‐analyses	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comparing	  uncovered	  and	  covered	  SEMS	  (Table	  6)	  61-­‐66.	  Only	  trials	  in	  which	  stents	  were	  
inserted	   endoscopically	   and	   full-­‐text	   articles	   were	   included.	   Analysis	   of	   these	   trials	  
shows	   a	   number	   of	   pitfalls.	   There	   was	   no	   uniformity	   in	   the	   inclusion	   and	   exclusion	  
criteria.	   There	  was	   inconsistency	   in	   the	   inclusion	  of	   patients	  with	  metastatic	   disease	  
and	  poor	  performance	  status.	  Furthermore,	  definitions	  used	  and	  details	  of	  the	  causes	  
of	  stent	  dysfunction	  varied	  between	  the	  trials.	  A	  variety	  of	  different	  stents	  were	  used	  
and	  the	  stents	  used	  in	  the	  Isayama	  trial	  are	  not	  commercially	  available61.	  
The	   results	   of	   the	   randomised	   controlled	   trials	   are	   conflicting	   and	   inconclusive.	   The	  
Isayama	   and	   Kitano	   studies	   showed	   a	   significantly	   lower	   incidence	   of	   stent-­‐related	  
complications	  in	  the	  covered	  SEMS	  group	  compared	  to	  the	  uncovered	  group61,65.	  This	  
was	  in	  contrast	  to	  two	  studies	  (Telford	  et.	  al.	  and	  Lee	  et.	  al.),	  which	  showed	  a	  higher	  
incidence	  of	  stent-­‐related	  complications	  in	  the	  covered	  SEMS	  group63,66.	  The	  migration	  
rate	  of	  covered	  SEMS	  in	  the	  Telford	  study	  was	  particularly	  high	  (11.8%).	  In	  all	  studies	  
except	   the	   Isayama	   study	   stent	  blockage	  due	   to	  particle	  occlusion	  was	  higher	   in	   the	  
covered	   SEMS	   group.	   In	   two	   studies	   (Kullman	   et.	   al.	   and	  Ung	   et.	   al.)	   there	  were	   no	  
significant	  differences	  in	  the	  overall	  incidence	  of	  stent-­‐related	  complications.	  However,	  
there	  was	  a	  significantly	  higher	  incidence	  of	  tumour	  ingrowth	  in	  the	  uncovered	  SEMS	  
group	  in	  the	  Kullman	  study62,64.	  
The	   findings	   of	   the	   meta-­‐analyses	   are	   also	   conflicting.	   The	   Almadi	   meta-­‐analysis	  
showed	   no	   difference	   in	   stent	   patency	   at	   6	   and	   12	   months67.	   There	   were	   no	  
differences	  in	  the	  rates	  of	  pancreatitis,	  cholecystitis,	  perforation,	  bleeding,	  cholangitis	  
or	  recurrent	  biliary	  obstruction.	  The	  Saleem	  meta-­‐analysis	  demonstrated	  that	  covered	  
SEMS	  provided	  a	  significantly	  longer	  mean	  stent	  patency	  of	  61	  days68.	  The	  mechanism	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of	  recurrent	   jaundice	   in	  the	  two	  groups	  differed	  with	  uncovered	  SEMS	  more	   likely	  to	  
block	   from	  tumour	   ingrowth	  and	  covered	  SEMS	  more	   likely	   to	  migrate	  or	  block	  with	  
debris.	  The	   latest	  meta-­‐analysis	  by	  Moole	  et.	  al.	   included	  13	  studies69.	  There	  was	  no	  
significant	   difference	   in	   overall	   adverse	   event	   rate	   or	   survival.	   Covered	   SEMS	   had	  
significantly	   lower	  occlusion	  rates,	  an	   increased	   incidence	  of	  migration	  and	   increased	  
odds	  for	  pancreatitis.1	  
The	   three	   meta-­‐analyses67-­‐69included	   studies	   that	   were	   excluded	   from	   the	   above	  
analysis.	   The	   Saleem	   meta-­‐analysis	   included	   two	   studies	   using	   percutaneous	   stent	  
insertion.	   Apart	   from	   these	   studies,	   the	   Almadi	   meta-­‐analysis	   included	   four	   studies	  
that	  were	  only	  published	  in	  abstract	  form.	  Neither	  of	  these	  meta-­‐analyses	  included	  the	  
Ung	   or	   Lee	   studies,	   as	   these	   had	   not	   been	   published	   at	   the	   time	   of	   the	   meta-­‐
analysis64,66.	   The	  Moole	  meta-­‐analysis	   included	   the	  Ung	  and	   Lee	   studies	   as	  well	   as	   a	  
randomised	   control	   trial	   (Krokidis	   et.	   al.)	   using	   percutaneously	   placed	   SEMS	   and	   a	  
number	   of	   non-­‐randomised	   and	   retrospective	   studies64,66,70.	   All	   three	  meta-­‐analyses	  
are	   limited	   by	   a	   small	   number	   of	   analysed	   studies	   and	   lack	   of	   uniform	   end-­‐points.	  
Almadi	   et.	   al.	   point	   out	   the	   need	   for	   standardised	   selection	   criteria,	   technical	  
approaches	  and	  outcomes/endpoints.	  
In	  conclusion,	  an	  analysis	  of	  the	  results	  above	  suggests	  that	  uncovered	  SEMS	  are	  less	  
likely	   to	  migrate	   than	  covered	  SEMS.	  Covered	  SEMS	  are	   less	   likely	   to	  occlude	  due	   to	  
tumour	  ingrowth	  but	  are	  more	  likely	  to	  block	  due	  to	  proximal	  tumour	  overgrowth	  and	  






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7. New	  Developments	  and	  Strategies
Drug-­‐eluting	  Stents	  
Drug-­‐eluting	   stents	   in	   which	   the	   chemotherapeutic	   agent	   is	   incorporated	   into	   the	  
covering	  membrane	  may	  improve	  stent	  patency	  by	  local	  delivery	  of	  chemotherapeutic	  
agents,	  theoretically	  preventing	  or	  delaying	  tumour	  ingrowth	  or	  overgrowth.	  Paclitaxel	  
is	  the	  most	  frequently	  used	  stent-­‐eluting	  chemotherapeutic	  agent.	  Gemcitabine	  and	  5-­‐
fluorouracil,	   the	  most	   commonly	  used	   systemic	   chemotherapeutic	  agents	   in	  patients	  
with	  malignant	  biliary	  obstruction,	  are	  hydrophilic,	  resulting	  in	  initial	  rapid	  drug	  release	  
but	   little	   sustained	   elution	  when	   incorporated	   into	   a	  membrane71.	   Current	   evidence	  
suggests	  that	  drug-­‐eluting	  SEMS	  are	  safe	  but	  there	  is	  no	  strong	  evidence	  that	  they	  are	  
more	  effective	  than	  standard	  SEMS.	  The	  majority	  of	  the	  studies	  have	  been	  conducted	  
in	   animals.	   There	   is	   only	   one	   study	   in	   humans	   comparing	   drug-­‐eluting	   stents	   to	  
conventional	  stents	  (Table	  7)	  72-­‐77.	  
Bioabsorbable	  stents	  
Self-­‐expanding	  bioabsorbable	  stents	  have	  been	  studied	  in	  both	  malignant	  and	  benign	  
disease.	   The	   main	   potential	   advantage	   of	   these	   stents	   is	   avoiding	   an	   additional	  
endoscopic	   procedure	   to	   remove	   the	   stent,	   an	   unlikely	   event	   in	   malignant	   biliary	  
obstruction.	  These	  stents	  are	  therefore	  more	  likely	  to	  be	  of	  benefit	  in	  the	  treatment	  of	  
patients	  with	  benign	  strictures	  and	  bile	  leaks.	  Materials	  used	  to	  construct	  these	  stents	  
include	  polylactide	  and	  polydioxanone	  that	  exert	  weaker	  radial	  force	  than	  nitinol	  SEMS	  
and	  stent	  expansion	  with	  balloon	  dilatation	  is	  required	  for	  optimal	  deployment.	  These	  
stents	   require	   further	   development	   and	   clinical	   investigation	   before	   routine	   clinical	  
use59,78-­‐80.	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Table	  7.	  Studies	  on	  drug-­‐eluting	  biliary	  stents72-­‐77
Study	   Subjects	   Drug	   Result	  
Lee	  (2005)	   2	  pigs	   Paclitaxel	   Drug	  release	  and	  histological	  
changes	  best	  with	  10%	  wt/v	  
paclitaxel	  stent	  
Suk	  (2007)	   21	  humans	   Paclitaxel	   Mean	  patency	  429	  days;	  mean	  
survival	  350	  days	  
Lee	  (2009)	   11	  dogs	   Paclitaxel	   Mucosal	  hyperplasia	  in	  3/6	  
dogs	  with	  a	  drug	  eluting	  stent	  




2	  pigs	   Gemcitabine	   Increasing	  inflammation	  as	  the	  
concentration	  of	  gemcitabine	  
is	  increased	  
Jang	  (2012)	   8	  pigs	   Paclitaxel	   Correlated	  serum	  paclitaxel	  
levels	  in	  pluronic-­‐containing	  
membranes	  
Jang	  (2013)	   106	  humans	   Paclitaxel	   Prospective	  comparative	  study	  
comparing	  60	  patients	  who	  
received	  drug-­‐eluting	  stents	  
vs.	  46	  who	  received	  standard	  
covered	  stents.	  
No	  difference	  in	  
complications.	  
No	  significant	  difference	  in	  
stent	  patency	  or	  survival.	  
(Trend	  towards	  improved	  
patency	  in	  the	  drug	  eluting	  
group)	  
Multiple	  Plastic	  Stents	  
Multiple	   plastic	   stents	   have	   been	   used	   in	   the	   management	   of	   benign	   strictures.	   A	  
number	  of	  randomised	  trials	  have	  compared	  multiple	  plastic	  stents	  to	  covered	  SEMS	  in	  
patients	   with	   strictures	   due	   to	   chronic	   pancreatitis	   and	   anastomotic	   strictures	  
following	  orthotopic	   liver	   transplantation81-­‐87.	   Stricture	   resolution	   rates	  are	   similar	   in	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patients	  treated	  with	  covered	  SEMS	  and	  multiple	  plastic	  stents.	  In	  a	  study	  on	  patients	  
with	  chronic	  pancreatitis,	  Siiki	  et.	  al.	   showed	  a	   trend	   towards	  more	  durable	  stricture	  
resolution	  with	   covered	   SEMS86.	   Patients	   treated	  with	   covered	   SEMS	   required	   fewer	  
endoscopic	  interventions.	  
There	   have	   been	   no	   randomised	   control	   trials	   comparing	   multiple	   plastic	   stents	   to	  
SEMS	   in	  patients	  with	  malignant	  biliary	  obstruction.	   It	  has	  been	  shown	   that	  multiple	  
plastic	  stents	  have	  a	  longer	  patency	  in	  patients	  with	  benign	  strictures.	  Lawrence	  et.	  al.	  
performed	  a	  retrospective	  review	  of	  20	  patients	  with	  distal	  malignant	  biliary	  strictures	  
who	   received	   double	   plastic	   stents88.	   The	   median	   stent	   patency	   was	   221	   days	  
approaching	   the	   stent	   patency	   achieved	   with	   SEMS.	   Multiple	   plastic	   stents	   may	   be	  
more	  cost	  effective	  than	  SEMS.	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1.2	  Ethics	  
Ethical	  approval	   for	   the	  trial	  was	  obtained	   from	  the	  University	  of	  Cape	  Town	  Human	  
Research	   Ethics	   Committee	   (HREC).	   The	   HREC	   reference	   number	   is	   144/2007.	   The	  
amended	  protocol	  that	  was	  submitted	  to	  the	  HREC	  can	  be	  found	  in	  Appendix	  1	  and	  the	  
approval	  letter	  can	  be	  found	  in	  Appendix	  2.	  
Patients	   were	   only	   included	   in	   the	   study	   after	   giving	   their	   informed	   consent.	   The	  
patient	  information	  form	  and	  consent	  form	  can	  be	  found	  in	  Appendix	  3.	  There	  was	  no	  
additional	   risk,	   cost	   or	   investigations	   for	   patients	   included	   in	   the	   study	   and	   their	  
treatment	   did	   not	   differ	   substantially	   from	   the	   treatment	   that	   they	   would	   have	  
received	  if	  not	  included	  in	  the	  study.	  
Once	  patients	  were	  entered	  in	  the	  trial	  their	  demographic	  data	  was	  captured.	  Patients	  
were	   followed	   up	  monthly	   until	   death.	   The	   forms	   used	   to	   capture	   the	   data	   can	   be	  
found	  in	  Appendix	  4.	  	  The	  completed	  forms	  will	  be	  destroyed	  once	  the	  study	  has	  been	  
published.	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1.3	  Journal	  for	  submission	  
The	  manuscript	  will	  be	  submitted	  to	  the	  South	  African	  Journal	  of	  Surgery.	  There	  have	  
been	  a	  number	  of	  trials	  comparing	  metal	  and	  plastic	  stents	   in	  distal	  malignant	  biliary	  
obstruction.	   As	   far	   as	   we	   are	   aware	   this	   is	   the	   first	   prospective	   randomised	   trial	  
comparing	   different	   types	   of	   biliary	   stents	   in	   Africa	   and	   we	   thus	   felt	   it	   would	   be	  
appropriate	  to	  submit	  the	  manuscript	  to	  a	  local	  journal.	  
The	  instructions	  for	  the	  authours	  can	  be	  found	  in	  Appendix	  5.	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Chapter	  2:	  Publication	  Ready	  Manuscript	  
1. Introduction
Tumours	   causing	   distal	   malignant	   biliary	   obstruction	   may	   arise	   in	   the	   head	   of	   the	  
pancreas,	   duodenum,	   ampulla	   or	   distal	   common	   bile	   duct.	   Pancreatic	   ductal	  
adenocarcinoma	  account	   for	   about	   two	   thirds	  of	   these	   cases,	   followed	  by	  ampullary	  
cancers	  (about	  20%)	  and	  distal	  cholangiocarcinomas	  (15%).	  Eighty	  percent	  of	  patients	  
who	  present	  with	  distal	  malignant	   biliary	   obstruction	   are	  not	   candidates	   for	   surgical	  
resection	  and	  require	  palliative	  treatment1.	  Endoscopic	  biliary	  stenting	  has	  become	  the	  
preferred	   method	   for	   relieving	   obstructive	   jaundice	   in	   these	   patients2.	   There	   have	  
been	  significant	  advances	  in	  stent	  technology	  since	  the	  first	  plastic	  endoscopic	  biliary	  
stent	   was	   placed	   in	   19793.	   A	   major	   improvement	   was	   the	   development	   of	   self-­‐
expanding	  metal	  stents	  (SEMS).	  Initially	  SEMS	  were	  uncovered	  but	  there	  are	  now	  also	  
commercially	   available	   fully	   covered	   and	  partially	   covered	   SEMS.	   There	   have	  been	   a	  
number	  of	   studies	   comparing	  plastic	   stents	   to	   SEMS,	  but	  no	   such	   studies	  have	  been	  
performed	   in	   an	   African	   institution4-­‐9.	   The	   studies	   that	   have	   been	   conducted	   have	  
consistently	  shown	  that	  plastic	  stents	  have	  a	  higher	  occlusion	  rate	  and	  shorter	  patency	  
compared	   to	   SEMS.	   Plastic	   stents	   do	   have	   some	   advantages	   over	   SEMS.	   They	   are	  
cheaper	  and	  are	  easily	  removable,	  as	  opposed	  to	  in	  particular	  non-­‐covered	  SEMS.	  	  
2. Aim
The	  aim	  of	   this	  study	  was	  to	  determine	  the	  safety	  and	  clinical	  effectiveness	  of	  single	  
10Fr	  plastic	  biliary	  stents	  compared	  to	  uncovered	  self-­‐expanding	  metal	  stents	  for	  the	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palliative	  treatment	  of	  patients	  with	  inoperable	  distal	  malignant	  biliary	  obstruction	  in	  
Groote	  Schhur	  Hospital.	  
3. Patients	  and	  Methods
Between	  January	  2009	  and	  December	  2013	  eligble	  patients	  with	  symptomatic	  jaundice	  
due	   to	   irresectable	   periampullary	   cancer	   were	   randomised	   to	   either	   a	   10Fr	   plastic	  
stent	  or	  an	  uncovered	  SEMS.	  The	  inclusion	  and	  exclusion	  criteria	  are	  shown	  in	  Table	  1.	  
Table	  1.	  Inclusion	  and	  exclusion	  criteria	  
*ECOG	  Eastern	  Cooperative	  Oncology	  Group
Inclusion	  Criteria	   Exclusion	  Criteria	  
1) Clinical	  data	  suggestive	  of	  a	  distal
malignant	  bile	  duct	  obstruction.
2) 18	  years	  of	  age	  or	  older
3) Information	  given	  and	  informed
consent	  obtained
4) Bilirubin	  >50	  mol/L	  (normal	  26	  mol/L)
5) Typical	  radiological	  appearance	  of
malignant	  common	  bile	  duct	  stenosis
at	  ERCP
6) Proximal	  margin	  of	  malignant	  bile
duct	  stenosis	  >2	  cm	  from	  the	  hepatic
confluence
7) ECOG*	  performance	  status	  0-­‐2
1) Metastatic	  disease
2) Resectable	  patients
3) Previous	  gastric	  surgery	  or
duodenal	  obstruction
preventing	  ERCP
4) Previous	  inclusion	  in	  the	  study
5) Participation	  in	  another	  clinical
trial	  in	  the	  preceding	  90	  days
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Randomisation	   was	   on	   a	   1:1	   basis,	   using	   sequentially	   numbered	   opaque	   envelopes.	  
Patients	  were	   randomised	  once	  a	   guidewire	  had	   successfully	   been	  positioned	  across	  
the	   stricture	   during	   ERCP.	   A	   standard	   polyethylene	   plastic	   stent	   (BostonScientific,	  
Massachusetts,	  USA)	  with	  proximal	  and	  distal	  flanges	  or	  an	  uncovered	  SEMS	  (Wallflex,	  
BostonScientific,	  Massachusetts,	  USA)	  with	  a	  10mm	  diameter	  was	  used.	  The	  lengths	  of	  
the	   stents	   were	   chosen	   according	   to	   the	   extent	   of	   the	   stricture.	   Adhering	   to	   the	  
CONSORT	  criteria	  all	  patients	  presenting	  with	  periampullary	  carcinoma	  were	  entered	  
in	  a	  database.	  Patients	  were	  evaluated	  with	  US,	  CT	  and/or	  MRI	  and	  reviewed	  at	  a	  MDT	  
meeting	  to	  assess	  resectability.	  
Demographic	   and	   clinical	   data,	   post-­‐procedural	   duration	   of	   hospital	   stay,	  
complications	   and	   the	   need	   for	   any	   additional	   interventions	   were	   documented.	  
Patients	  were	  followed	  up	  monthly	  for	  12	  months	  or	  until	  time	  of	  death.	  At	  follow-­‐up	  
liver	   function	   tests	   were	   performed	   in	   patients	   with	   a	   clinical	   suspicion	   of	   stent	  
dysfunction.	   Re-­‐interventions	  were	   documented.	   For	   patients	  with	   stent	   dysfunction	  
the	   salvage	   strategy	  was	   left	   to	   the	   treating	   endoscopist.	   Any	   hospital	   readmissions	  
were	   recorded,	   specifying	   the	   indication	   for	   admission.	   The	   primary	   endpoint	   in	   the	  
study	  was	  effective	  palliation	  of	  biliary	  obstruction,	  defined	  as	  a	   functioning	   stent	  at	  
time	   of	   death	   or	   at	   12	   months.	   Secondary	   endpoints	   included	   the	   ability	   to	   safely	  
deploy	  the	  stent	   in	  a	  satisfactory	  position,	  procedure-­‐related	  adverse	  events	  and	  the	  
need	   for	   re-­‐intervention.	   Ethical	   approval	   for	   the	   trial	   and	   the	   registries	   from	  which	  
data	  was	  extracted	  was	  obtained	  from	  the	  University	  of	  Cape	  Town	  Human	  Research	  
Ethics	  Committee	  (HREC	  no:	  144/2007).	  
46	  
Statistical	  analysis	  
Descriptive	   statistics	   as	   appropriate	   were	   used	   to	   present	   clinical	   and	   treatment	  
characteristics	  and	  outcome	  of	   the	   study	   subjects.	  The	  Fisher	  exact	   test	  and	   student	  
(unpaired)	  t-­‐test	  were	  used	  to	  assess	  differences	  between	  the	  two	  groups.	  The	  Kaplan-­‐
Meier	  method	  was	   used	   to	   estimate	   survival	   time	   and	   probabilities	   for	   survival	   and	  
stent	   patency	   times.	   The	   censored	   events	   for	   stent	   patency	  were	   loss	   to	   follow	   up,	  
death,	  or	  patency	  after	  1	  year	  of	  follow	  up.	  Censored	  events	  for	  survival	  were	  loss	  to	  
follow	  up.	  Differences	  in	  survival	  and	  stent	  patency	  probabilities	  were	  calculated	  with	  
the	  log-­‐rank	  test	  using	  Stata	  (version	  13.1;	  Stata	  Corp,	  College	  Station,	  Texas,	  USA).	  A	  
p<0.05	  was	  considered	  statistically	  significant	  where	  appropriate.	  
4. Results
A	  CONSORT	  flowchart	   illustrating	  the	   inclusion	  of	  patients	   is	  shown	  in	  Figure	  1.	  Forty	  
patients	  with	  obstructive	  jaundice	  due	  to	  periampullary	  cancer	  were	  randomised.	  The	  
demographic	   and	   clinical	   characteristics	   of	   the	   patients	   are	   summarized	   in	   Table	   2.	  
There	  were	  no	  significant	  differences	  between	  the	  two	  groups.	  The	  intention	  to	  treat	  
cohort	  included	  17	  men	  and	  23	  women,	  with	  a	  median	  age	  of	  68	  years	  (range	  50-­‐85).	  
Thirty-­‐six	   patients	   had	   pancreatic	   cancer	   and	   4	   had	   distal	   cholangiocarcinoma.	   No	  
patients	  had	  ampullary	  or	  duodenal	  carcinoma.	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Figure	  1.	  Consort	  Flow	  Diagram	  
Follow-­‐up	  
Patients	  were	  followed	  up	  until	  death	  or	  for	  12	  months.	  In	  the	  plastic	  stent	  group	  one	  
patient	  was	  lost	  to	  follow	  up	  after	  three	  months	  and	  another	  withdrew	  consent.	  These	  
patients	  were	  included	  in	  the	  final	  intention	  to	  treat	  analysis.	  
48	  
Table	  2.	  Patient	  demographic	  and	  clinical	  characteristics	  at	  inclusion	  
Survival	  
Median	  survival	  in	  the	  two	  groups	  was	  similar	  as	  assessed	  by	  the	  Kaplan-­‐Meier	  method	  
and	   the	   log-­‐rank	   test	   (p=0.18)	   (figure	  2).	   Thirty	  patients	   (75%)	  died	  during	   the	   study	  
Plastic	  Stent	   SEMS	   p-­‐value	  
No	  of	  Patients	  	  n	  (%)	   19	  (47.5%)	   21	  (52.5%)	  
Males/Females	   8/11	   9/12	   p=0.61	  

































Median	  tumour	  size	  cm	  
(range)	  
3.0	  (1.0-­‐4.9)	   3.0	  (2.0-­‐6.8)	   p=0.55	  
Median	  Bilirubin	  umol/l	  
(range)	  
338	  (71-­‐651)	   357	  (40-­‐681)	   p=0.66	  
Median	  Ca-­‐19.9	  U/ml	  
(range)	  
392	  (1-­‐>1000)	   256	  (16-­‐	  >1	  000)	   p=0.43	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period,	  13	  in	  the	  plastic	  stent	  group	  and	  19	  in	  the	  SEMS	  group.	  The	  median	  survival	  in	  
the	  SEMS	  group	  was	  114	  days	  compared	  to	  107	  days	  in	  the	  plastic	  stent	  group.	  
Figure	  2.	  Kaplan	  Meier	  Graph	  comparing	  survival	  in	  the	  two	  groups	  
Stent	  patency	  
There	  was	   a	   significant	   difference	   in	   stent	   patency	   (p=0.043)	  with	   one	   of	   the	   SEMS	  
(4.7%)	  and	  seven	  of	  the	  plastic	  stents	  (38.8%)	  occluding	  during	  the	  study	  period.	  The	  
patient	   with	   the	   blocked	   SEMS	   had	   a	   stone	   above	   the	   malignant	   stricture	   that	  
impacted	   in	   the	  stent	  3	  days	  after	   insertion.	  The	  difference	   in	  stent	  patency	  became	  
significant	  after	  six	  months	  (Table	  3,	  Figure	  3).	  The	  plastic	  stents	  had	  25%	  failure	  at	  60	  


























Table	  3.	  Survival	  and	  stent	  blockage	  in	  both	  groups	  




0/18	   1/21	   1.0	  
At	  1	  month	  
(blocked/alive)	  
1/15	   1/20	   0.65	  
At	  3	  months	  	  
(blocked/alive)	  
2/11	   1/11	   0.3306	  
At	  6	  months	  
(blocked/alive)	  
5/7	   1/7	   0.0395	  
At	  9	  months	  
(blocked/alive)	  
5/5	   1/3	   0.0395	  
At	  12	  months	  
(blocked/alive)	  
6/4	   1/2	   0.0174	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Figure	  3.	  Kaplan	  Meier	  Graph	  comparing	  stent	  patency	  in	  the	  two	  groups	  
Stent	  deployment	  and	  complications	  
All	   patients	   had	   successful	   stent	   deployment	   and	   there	   were	   no	   ERCP	   related	  
complications.	   There	   were	   no	   unanticipated	   adverse	   device	   effects,	   and	   no	   deaths	  
were	   attributed	   to	   the	   investigational	   device.	   In	   two	   patients	   (one	   in	   each	   group)	  
jaundice	  did	  not	  subside	  despite	  patent	  stents.	  The	  cause	  of	  the	  prolonged	  cholestasis	  
could	   not	   be	   ascertained.	   Four	   of	   the	   seven	   patients	   with	   blocked	   plastic	   stents	  
presented	   with	   cholangitis.	   One	   patient	   in	   each	   group	   developed	   gastric	   outlet	  
obstruction.	  They	  were	  both	  treated	  with	  an	  uncovered	  duodenal	  SEMS.	  One	  patient	  
in	   the	  SEMS	  group	  was	  admitted	  with	  a	  bleeding	  gastric	  ulcer.	   Seven	  patients	   in	   the	  
plastic	  stent	  group	  spent	  a	  total	  of	  44	  days	  in	  hospital	  with	  stent	  related	  complications	  
compared	  to	  one	  patient	  in	  the	  SEMS	  group	  who	  was	  hospitalized	  for	  21	  days.	  None	  of	  

























This	   is	   the	   first	   randomised	   control	   trial	   from	   an	   African	   institution	   that	   compares	  
uncovered	  SEMS	  with	  traditional	  plastic	  stents	  for	  the	  endoscopic	  palliation	  of	  jaundice	  
in	  patients	  with	  periampullary	  tumours.	  The	  findings	  in	  the	  study	  were	  in	  keeping	  with	  
previously	  reported	  results,	  comparing	  uncovered	  SEMS	  and	  plastic	  stents,	  showing	  a	  
lower	   incidence	  of	  stent	  dysfunction	  and	   longer	  stent	  patency	   in	  the	  SEMS	  groups4-­‐9.	  
However,	   the	   improvement	   in	   stent	   patency	   comes	   at	   a	   considerable	   expense,	  with	  
SEMS	  being	  up	  to	  10	  times	  more	  expensive	  than	  plastic	  stents.	  These	  costs	  are	  offset	  
by	   the	   increased	   need	   for	   re-­‐intervention	   in	   patients	   with	   plastic	   stents10,11.	   In	   this	  
study	   the	   difference	   became	   significant	   after	   six	  months	   of	   follow	   up.	   Although	   the	  
study	  did	  not	  address	  the	  cost	  effectiveness	  of	  SEMS	  it	  has	  been	  shown	  that	  SEMS	  are	  
more	  cost	  effective	  in	  patients	  with	  a	  longer	  projected	  survival.	  
Follow	  up	  of	  patients	  in	  our	  patient	  population	  can	  be	  challenging.	  In	  spite	  of	  this	  only	  
one	  patient	  was	  lost	  to	  follow	  up.	  In	  our	  healthcare	  environment,	  some	  patients	  who	  
reside	   in	   rural	   areas	   have	   poor	   access	   to	   health	   facilities.	   These	   patients	   often	  
experience	   considerable	   delays	   in	   getting	   appropriate	   treatment	  when	   they	   develop	  
stent	  dysfunction.	  Increased	  use	  of	  SEMS	  in	  these	  patients	  is	  particularly	  useful.	  
There	  have	  been	  a	  number	  of	  randomised	  control	   trials	  comparing	  different	  types	  of	  
SEMS	   (covered,	  partially	   covered,	  uncovered)	   to	  each	  other	   and	   there	  has	  been	  one	  
randomised	   control	   trial	   comparing	   covered	   SEMS	   and	   plastic	   stents.	   Although	   the	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reason	  for	  stent	  failure	  differs	  with	  the	  different	  types	  of	  SEMS	  (ingrowth	  in	  uncovered	  
SEMS	  vs.	  migration	  in	  covered	  SEMS),	  patency	  rates	  are	  similar12-­‐18.	  
As	   the	   intention	  of	   the	   trial	  was	   to	   test	   the	   stents	   in	  patients	  with	  a	   life	  expectancy	  
over	   six	   months	   only	   patients	   without	   metastatic	   disease	   and	   a	   good	   performance	  
status	   (ECOG	   0-­‐2)	   were	   included.	   The	   strict	   inclusion	   criteria	   resulted	   in	   a	   long	  
enrollment	  period	  and	  was	  the	  main	  reason	  for	  the	  small	  number	  of	  patients	  included	  
in	  the	  study.	  
None	   of	   the	   patients	   in	   this	   study	   had	   a	   tissue	   diagnosis	   or	   received	   palliative	  
chemotherapy.	  The	  diagnosis	  of	  malignancy	  was	  based	  on	  the	  clinical	  presentation	  and	  
cross	  sectional	  imaging.	  With	  improved	  access	  to	  endoscopic	  ultrasound	  we	  now	  more	  
frequently	  attempt	  to	  get	  a	   tissue	  diagnosis	  and	  a	  greater	  proportion	  of	  patients	  are	  
receiving	  palliative	  chemotherapy.	  
Multiple	  plastic	  stents	  are	  frequently	  used	  to	  treat	  patients	  with	  benign	  strictures	  and	  
have	  been	  shown	  to	  have	  better	  patency	  rates	  than	  single	  plastic	  stents.	   It	  has	  been	  
suggested	  that	  that	  multiple	  plastic	  stents	  may	  have	  a	  stent	  patency	  similar	  to	  SEMS	  in	  
malignant	   strictures19.	   There	   has	   never	   been	   a	   randomised	   trial	   comparing	  multiple	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  Chapter	  3:	  Appendices	  
3.1	  Appendix	  1:	  Protocol	  
Title	   of	   Project:	   Distal	  malignant	   biliary	   obstruction:	   A	   prospective	   randomised	   trial	  
comparing	  metal	  and	  plastic	  stents	  in	  the	  palliation	  of	  symptomatic	  jaundice	  at	  Groote	  
Schuur	  Hospital.	  
Principle	  Investigator:	  M	  Bernon	  
Co-­‐investigators:	  J	  Shaw,	  PC	  Bornman,	  JEJ	  Krige	  
1. Background	  and	  literature
Symptomatic	  obstructive	  jaundice	  remains	  a	  distressing	  symptom	  in	  patients	  who	  have	  
inoperable	  malignant	  distal	  common	  bile	  duct	  strictures.	  Endoscopic	  biliary	  stenting	  is	  
a	  well-­‐established	  palliative	  treatment	  in	  this	  context,	  and	  surgical	  bypass	  is	  no	  longer	  
the	  only	  therapeutic	  option	  available	  to	  patients.	  
Surgical	  bypass	  was	  considered	  the	  gold	  standard	  and	  is	  the	  most	  durable	  method	  of	  
palliating	   obstructive	   jaundice	   in	   patients	   with	   irresectable	   distal	   malignant	   biliary	  
obstruction.	   Stent	   dysfunction	   results	   in	   morbidity,	   mortality	   and	   reduction	   in	   the	  
quality	   of	   life.	   Surgery	   is	   however	   associated	   with	   increased	   early	   morbidity	   and	   a	  
longer	  initial	  hospital	  stay.	  In	  addition	  many	  of	  these	  patients	  are	  old	  and	  frail	  and	  not	  
good	  surgical	  candidates1-­‐3.	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The	  majority	   of	   patients	   presenting	   to	   our	   institution	  with	  malignant	   distal	   common	  
bile	  duct	  strictures	  are	  not	  good	  surgical	  candidates	  and	  endoscopic	  stent	  insertion	  is	  
the	   treatment	   modality	   of	   choice.	   Percutaneous	   stent	   insertion	   is	   considered	   when	  
endoscopic	   stent	   insertion	   fails	   or	   is	   not	   possible.	   The	   consensus	   is	   that	   this	   offers	  
good	   palliation	   of	   symptomatic	   obstructive	   jaundice	   with	   lower	   morbidity	   and	  
mortality	  than	  surgical	  bypass,	  which	  is	  particularly	  relevant	  in	  patients	  with	  limited	  life	  
expectancy.	  
There	  are	  several	  trials	  demonstrating	  superior	  results	  of	  stenting	  compared	  to	  surgery	  
with	   regard	   to	   morbidity,	   mortality	   and	   cost	   effectiveness	   in	   the	   short	   term4-­‐9.	  
Recurrent	   blockages	   particularly	   with	   plastic	   stents,	   however,	   have	   been	   shown	   to	  
erode	  this	  benefit	  especially	  in	  patients	  who	  survive	  for	  longer	  than	  six	  months10.	  The	  
current	  area	  of	  interest	  is	  plastic	  versus	  metal	  stents	  with	  regard	  to	  patency,	  cost	  and	  
quality	  of	  life.	  The	  best	  method	  of	  selecting	  patients	  to	  receive	  metal	  or	  plastic	  stents	  
in	  a	  resource	  limited	  environment	  remains	  topical	  due	  to	  the	  great	  discrepancy	  in	  cost	  
(plastic	   stents	   cost	   approximately	   R250.00	   and	  metal	   stents	   approximately	   R4500	   in	  
State	   hospitals).	   The	   international	   literature	   shows	   that	   metal	   stents	   have	   lower	  
occlusion	  rates	  and	  are	  more	  cost	  effective	  than	  plastic	  stents	  if	  survival	  is	  estimated	  to	  
be	   longer	   than	  3	  months.	   This	   saving	   is	   as	  a	   result	  of	   fewer	  hospital	   admissions	  and	  
repeat	  endoscopic	  procedures	  to	  exchange	  blocked	  stents.	  In	  the	  context	  of	  the	  South	  
African	  State	  sector	  one	  has	  to	  factor	   in	  the	  vast	  distances	  patients	  have	  to	  travel	   to	  
access	  medical	  care.	  This	  results	   in	   long	  periods	  away	  from	  family	  and	  social	  support	  
structures,	  impacting	  on	  quality	  of	  life.	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There	  have	  been	  no	   local	   randomised	   trials	   comparing	  metal	   and	  plastic	   stents.	  Our	  
current	  practice	  has	  been	  to	  place	  a	  plastic	  stent.	  If	  life	  expectancy	  is	  estimated	  to	  be	  
longer	  than	  3-­‐months,	  the	  endoscopist	  may	  elect	  to	  use	  a	  metal	  stent.	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2. Aims
Hypothesis	  to	  be	  tested	  
Metal	  stents	  are	  superior	  to	  plastic	  stents	  in	  terms	  of	  patency,	  resulting	  in	  more	  cost	  
effective	  palliation	  of	  inoperable	  distal	  malignant	  biliary	  obstruction	  and	  better	  quality	  
of	  life	  due	  to	  fewer	  hospital	  admissions	  and	  less	  re-­‐interventions.	  
	  Primary	  end	  point	  
To	  assess	  effective	  palliation	  of	  biliary	  obstruction,	  defined	  as	  a	  functioning	  stent	  at	  the	  
time	  of	  death	  or	  at	  12	  months.	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Secondary	  endpoints	  
	  Ability	  to	  safely	  deploy	  the	  stent	  in	  a	  satisfactory	  position,	  procedure-­‐related	  adverse	  
events	  and	  the	  need	  for	  re-­‐intervention.	  
Methods	  
Study	  design	  
Prospective	  randomised	  trial	  to	  compare	  uncovered	  self-­‐expanding	  metal	  stent	  (SEMS)	  
or	  plastic	  stent	  in	  the	  palliation	  of	  distal	  malignat	  biliary	  obstruction.	  
Study	  population	  
All	  patients	  with	  symptomatic	  jaundice	  due	  to	  an	  irresectable	  distal	  malignant	  stricture	  
will	   be	   entered	   in	   a	   database	   and	   assessed	   for	   inclusion	   into	   the	   study.	   In	   order	   to	  
exclude	   patients	   with	   a	   short	   life	   expectancy,	   patients	   with	  metastatic	   disease	   or	   a	  
poor	  performance	  status	  will	  be	  excluded	   (Table	  1	   -­‐	   inclusion	  and	  exclusion	  criteria).	  
Patients	  will	  be	  evaluated	  with	  US,	  CT	  and/or	  MRI	  and	  reviewed	  at	  a	  multi-­‐disciplinary	  
meeting,	  to	  assess	  resectability.	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Table	  1.	  Inclusion	  and	  exclusion	  criteria	  
Informed	  consent	  
Potential	   candidates	   for	   the	   study	   will	   be	   given	   an	   information	   sheet	   and	   will	   only	  
considered	  for	  inclusion	  after	  giving	  informed	  consent.	  The	  consent	  must	  be	  obtained	  
by	  the	  principle	  investigator	  or	  one	  of	  the	  co	  investigators.	  
Randomisation	  
Inclusion	  Criteria	   Exclusion	  Criteria	  
1. Clinical	  data	  suggestive	  of	  a
distal	  malignant	  bile	  duct
obstruction.
2. 18	  years	  of	  age	  or	  older
3. Information	  given	  and	  informed
consent	  obtained
4. Bilirubin	  >50	  mol/L	  (normal	  26
mol/L)
5. Typical	  radiological	  appearance
of	  malignant	  common	  bile	  duct
stenosis	  at	  ERCP
6. Proximal	  margin	  of	  malignant
bile	  duct	  stenosis	  >2	  cm	  from
the	  hepatic	  confluence
7. ECOG*	  performance	  status	  0-­‐2
1. Metastatic	  disease
2. Resectable	  patients
3. Previous	  gastric	  surgery	  or
duodenal	  obstruction
preventing	  ERCP
4. Previous	  inclusion	  in	  the	  study
5. Participation	  in	  another	  clinical
trial	  in	  the	  preceding	  90	  days
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Randomisation	  will	  be	  on	  a	  1:1	  basis,	  using	  sequentially	  numbered	  opaque	  envelopes,	  
once	  a	  guidewire	  had	  successfully	  been	  positioned	  across	  the	  stricture	  during	  ERCP.	  	  
Stents	  
A	   standard	  polyethylene	   (Cotton-­‐Huibrigste)	  plastic	   stent	   (Boston)	  with	  proximal	  and	  
distal	   flanges	   or	   an	   uncovered	   SEMS	   (Boston)	  with	   10mm	   diameter	  were	   used.	   The	  
lengths	  of	  the	  stents	  were	  chosen	  according	  to	  the	  extent	  of	  the	  stricture.	  	  
Follow	  up	  
Demographic	   and	   clinical	   data,	   post-­‐procedural	   duration	   of	   hospital	   stay,	  
complications	  and	  need	  for	  any	  additional	  interventions	  will	  be	  documented.	  Patients	  
will	  be	   followed	  up	  monthly	   for	  12	  months	  or	  until	   time	  of	  death.	  At	   follow	  up	   liver	  
function	   tests	   will	   be	   performed	   in	   patients	   with	   a	   clinical	   suspicion	   of	   stent	  
dysfunction.	  Re-­‐interventions	  and	  re-­‐admissions	  will	  be	  documented.	  For	  patients	  with	  
stent	   dysfunction	   the	   salvage	   strategy	   will	   be	   at	   the	   discretion	   of	   the	   treating	  
endoscopist.	  
Ethical	  Considerations	  
Ethical	  approval	  will	  be	  obtained	   from	  the	  Human	  Research	  Ethics	  Committee	  of	   the	  
University	   of	   Cape	   Town.	   The	   trial	   will	   be	   performed	   according	   to	   the	   guidelines	  
described	  in	  the	  Helsinki	  Declaration	  for	  biomedical	  research	  involving	  human	  subjects.	  
There	  will	  be	  no	  additional	  risk,	  cost	  or	  investigations	  to	  the	  patients.	  	  
If	  we	  are	  able	  to	  demonstrate	  the	  expected	  benefit	  of	   foreign	  experience	  with	  metal	  
stents	  (longer	  patency	  and	  fewer	  readmissions)	  our	  current	  practice	  of	  routine	  plastic	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stent	  use	  at	  Groote	  Schuur	  Hospital	  may	  change.	  This	  may	  benefit	  future	  patients	  and	  
allow	  more	  cost-­‐effective	  care.	  
Statistical	  planning	  
We	  plan	  to	  commence	  the	  study	  with	  a	  sample	  of	  15	  patients	  in	  each	  arm.	  The	  interim	  
results	  will	  allow	  us	  to	  be	  accurate	  in	  determining	  an	  appropriate	  sample	  size	  to	  give	  a	  
statistically	  significant	  result.	  
Use	  of	  Data	  
We	  will	  use	  a	  qualified	  statistician	  to	  analyse	  the	  data.	  A	  manuscript	  will	  be	  submitted	  
to	  a	  peer-­‐reviewed	  journal	  for	  publication.	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